Orientations

Smallpox and mpox (orthopoxviruses): WHO position paper

World Health Organization (WHO)

This position paper is concerned with vaccines and vaccination against mpox and smallpox. Since the publication of the 2014 meeting report on smallpox vaccines, and the 2022 interim guidance on mpox vaccines and immunization, there have been reported changes in the epidemiology of mpox, particularly in endemic settings, and new evidence has emerged regarding effectiveness, safety and public health benefits of vaccines. This document replaces the 2022 interim guidance on mpox vaccination and the 2014 meeting report on smallpox vaccines and smallpox vaccination. It contains off-label recommendations.

Auteurs

Langues

Année de publication

2024

Type

Orientations

Catégories

  • Vaccins et dispositifs d'administration

Maladies

  • Mpox
  • Variole

Organisations

  • Organisation Mondiale de la Santé (OMS)

Mpox-Policy

Vous pouvez trouver plus d’informations sur "Mpox-Policy" dans les rubriques suivantes :

TitreAuteurAnnéeTypeLangue
Smallpox and mpox (orthopoxviruses): WHO position paperWorld Health Organization (WHO)2024GuidanceAnglais, Français
Summary of WHO SAGE recommendations for mpox vaccines, including considerations for off-label useWorld Health Organization (WHO)2025PresentationAnglais
Off-label vaccine use: explanatory note for countriesWorld Health Organization (WHO)2024GuidanceAnglais
MVA-BN (‎Modified Vaccinia Ankara – Bavarian Nordic)‎ smallpox and mpox vaccine: Interim guidanceWorld Health Organization (WHO)2024GuidanceAnglais, Français
ETF statement on the use of Imvanex for the prevention of mpox in children below 12 years of ageEuropean Medicines Agency2024GuidanceAnglais
Regulatory & Policy Considerations for Mpox Vaccines in African CountriesWorld Health Organization (WHO), European Medicines Agency, Bavarian Nordic2025PresentationAnglais
LC16m8 (live-attenuated freeze-dried vaccinia) smallpox and mpox vaccine - Interim GuidanceWorld Health Organization (WHO)2025GuidanceAnglais, Français
Frequently Asked Questions (FAQ) on use of fractional dosing with intradermal administration of mpox MVA-BN vaccine in the context of vaccine supply-constrained outbreak responseWorld Health Organization (WHO)2025GuidanceAnglais

Ajouté par: Géraldine Nemrod

Ajouté le: 2024-11-19 14:59:31

Consultations: 1757

Liens

Ajouter une ressource